Last reviewed · How we verify
PF-06863135 + dexamethasone (pf-06863135-dexamethasone)
PF-06863135 + dexamethasone (pf-06863135-dexamethasone) is a marketed drug by Pfizer Inc. for Multiple Myeloma. It has generated $21.2B in revenue. The mechanism of action is not specified. This drug has 7 trials and 0 publications. It is a significant commercial entity. There are no pipeline developments mentioned.
At a glance
| Generic name | pf-06863135-dexamethasone |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Multiple Myeloma
Common side effects
Drug interactions
- Warfarin
- CYP3A4 inhibitors
- CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP1A2 inhibitors
- CYP1A2 inducers
- dexamethasone
Key clinical trials
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (PHASE3)
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (PHASE1)
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
- A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (PHASE3)
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (PHASE2)
- ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (PHASE2)
- PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06863135 + dexamethasone CI brief — competitive landscape report
- PF-06863135 + dexamethasone updates RSS · CI watch RSS
- Pfizer portfolio CI